CVRx Responds to Letter from Pointillist Family Office
CVRx, a Nasdaq-listed medical device company specializing in neuromodulation therapies for cardiovascular diseases, responded to a public letter from Pointillist Family Office. The board emphasized its dedication to shareholder interests, acknowledged the unique value of its Barostim therapy for heart failure, and recognized the undervaluation of t…